Search Result

Results for "

Amyloid-β Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (39) Akt (1) Apoptosis (8) Autophagy (7) Beta-secretase (5) Calcium Channel (1) Casein Kinase (1) CDK (1) Cholinesterase (ChE) (9) Endogenous Metabolite (1) GSK-3 (1) HDAC (1) HIV (4) Isotope-Labeled Compounds (1) mAChR (1) Monoamine Oxidase (2) mTOR (1) nAChR (2) NF-κB (2) NOD-like Receptor (NLR) (6) Notch (1) Nucleoside Antimetabolite/Analog (4) Organoid (1) PAI-1 (1) PI3K (1) Reactive Oxygen Species (1) Reverse Transcriptase (4) Tau Protein (1) γ-secretase (3)
By Research Areas:	Cancer (5) Infection (4) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (49)

By Targets:

Amyloid-β (39)

Akt (1)

Apoptosis (8)

Autophagy (7)

Beta-secretase (5)

Calcium Channel (1)

Casein Kinase (1)

CDK (1)

Cholinesterase (ChE) (9)

Endogenous Metabolite (1)

GSK-3 (1)

HDAC (1)

HIV (4)

Isotope-Labeled Compounds (1)

mAChR (1)

Monoamine Oxidase (2)

mTOR (1)

nAChR (2)

NF-κB (2)

NOD-like Receptor (NLR) (6)

Notch (1)

Nucleoside Antimetabolite/Analog (4)

Organoid (1)

PAI-1 (1)

PI3K (1)

Reactive Oxygen Species (1)

Reverse Transcriptase (4)

Tau Protein (1)

γ-secretase (3)

By Research Areas:

Cancer (5)

Infection (4)

Inflammation/Immunology (5)

Metabolic Disease (2)

Neurological Disease (49)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50900

gamma-Secretase Modulators Amyloid-β production Inhibitor; γ-Secretase Modulators	Amyloid-β	Neurological Disease
gamma-Secretase Modulators (Amyloid-β production inhibitor) is a Amyloid-β production inhibitor.

HY-N0931

Santacruzamate A 5+ Cited Publications CAY-10683	HDAC Amyloid-β	Neurological Disease Cancer
Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC₅₀ of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research .

HY-17631A

Edonerpic maleate T-817 maleate; T-817MA	Amyloid-β	Neurological Disease
Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-β peptides (Aβ).

HY-139324

Cu(II)GTSM 1 Publications Verification	GSK-3 Amyloid-β	Neurological Disease Cancer
Cu(II)GTSM, a cell-permeable Cu-complex, significantly inhibits GSK3β. Cu(II)GTSM inhibits Amyloid-β oligomers (AβOs) and decreases tau phosphorylation. Cu(II)GTSM also decreases the abundance of Amyloid-β trimers. Cu(II)GTSM is a potential anticancer and antimicrobial agent .

HY-P3244

D-KLVFFA	Amyloid-β	Neurological Disease
D-KLVFFA is the inhibitor of Amyloid-β assembly, with the IC₅₀ of 2.6 μM, that can be used in Alzheimer's disease study .

HY-153431

TRV-1387	Tau Protein Amyloid-β	Neurological Disease
TRV-1387 is a benzofurazan that inhibits the aggregation of tau and *amyloid-β* .

HY-P1962

β-Secretase inhibitor [Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)	Beta-secretase	Neurological Disease
β-Secretase inhibitor ([Asn670, Sta671, Val672]-Amyloid β Peptide (662-675)) is a β-secretase and BACE1 inhibitor (IC₅₀: 25 nM for β-secretase) .

HY-163441

BChE-IN-31	Cholinesterase (ChE)	Neurological Disease
BChE-IN-31 (Compound 14d) is a selective BChE inhibitor with an IC₅₀ of 65 nM. BChE-IN-31 inhibits the self-induced aggregation of neurotoxic amyloid-β (Aβ) peptide .

HY-167843

Alborixin	Akt PI3K Autophagy	Neurological Disease
Alborixin is an inhibitor of the PI3K-AKT pathway that induces autophagy. It promotes the clearance of intracellular and extracellular *amyloid-β* by upregulating autophagy-related proteins (such as BECN1, ATG5, ATG7) and enhancing lysosomal activity, thereby reducing *amyloid-β*-mediated neurotoxicity. Alborixin shows potential for research in Alzheimer's disease .

HY-121191

Bisnorcymserine N1,N8-Bisnorcymserine; (-)-Bisnorcymserine	Cholinesterase (ChE)	Neurological Disease
Bisnorcymserine ((-)-Bisnorcymserine) is an inhibitor for butyrylcholinesterase (BChE) with an IC₅₀ of 0.228 nM. Bisnorcymserine reduces the levels of amyloid-β peptide (Aβ), exhibits ameliorates the Alzheimer’s Disease in elderly rat models. Bisnorcymserine is blood-brain barrier penetrate .

HY-N2319

Dihydroergocristine mesylate DHEC mesylate	Amyloid-β	Neurological Disease
Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease *amyloid-β* peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively .

HY-163320

AChE/Aβ-IN-5	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-5 (compound AV-2) is a bifunctional inhibitor that targets AChE and auto-induced Aβ (Amyloid-β) aggregation. AChE/Aβ-IN-5 can significantly improve scopolamine- and Aβ-induced cognitive impairment in mice .

HY-14759

Aleplasinin PAZ-417	PAI-1 Amyloid-β	Neurological Disease
Aleplasinin is an orally active, potent, BBB-penetrated and selectiveSERPINE1 (PAI-1, Plasminogen activator inhibitor-1) inhibitor. Aleplasinin increases amyloid-β (Aβ) catabolism and ameliorates amyloid-related pathology. Aleplasinin improves memory deficiency. Aleplasinin can be used for Alzheimer's disease research .

HY-W010041

Scyllo-Inositol	Amyloid-β Endogenous Metabolite	Neurological Disease
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of *amyloid-β* peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .

HY-P5124

β-Amyloid peptide(16-20) KLVFF	Amyloid-β	Neurological Disease
β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of *Amyloid-β* (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH₂ residues added at N- and C-terminal ends to aid solubility) .

HY-N2319R

Dihydroergocristine mesylate (Standard) DHEC mesylate (Standard)	Amyloid-β	Neurological Disease
Dihydroergocristine (mesylate) (Standard) is the analytical standard of Dihydroergocristine (mesylate). This product is intended for research and analytical applications. Dihydroergocristine mesylate (DHEC mesylate) is a inhibitor of γ-secretase (GSI), reduces the production of the Alzheimer's disease *amyloid-β* peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (K_d) of 25.7 nM and 9.8 μM, respectively .

HY-B0116

Stavudine 3 Publications Verification d4T	Reverse Transcriptase HIV Nucleoside Antimetabolite/Analog NOD-like Receptor (NLR) Autophagy Apoptosis	Infection
Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis .

HY-B0116A

Stavudine sodium d4T sodium	Reverse Transcriptase HIV Nucleoside Antimetabolite/Analog NOD-like Receptor (NLR) Autophagy Apoptosis	Infection
Stavudine (d4T) sodium is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine sodium has activity against HIV-1 and HIV-2. Stavudine sodium also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine sodium reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine sodium induces apoptosis .

HY-130244

BACE1-IN-5	Beta-secretase	Neurological Disease
BACE1-IN-5 (Compound 15) is a *β-site amyloid* precursor protein cleaving enzyme 1 (BACE1)** inhibitor with an IC₅₀ of 9.1 nM, and also inhibits cellular amyloid-β (Aβ) with an IC₅₀ of 0.82 nM. BACE1-IN-5 has a medicinal chemistry that improves hERG inhibition and P-gp efflux .

HY-126047B

(R)-(+)-Anatabine	NF-κB Amyloid-β nAChR	Neurological Disease Inflammation/Immunology
(R)-(+)-Anatabine is an less active R-enantiomer of Anatabine. Anatabine is a potent α4β2 nAChR agonist . Anatabine inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment .

HY-13027

DAPT Maximum Cited Publications 101 Publications Verification GSI-IX	Organoid γ-secretase Amyloid-β Autophagy Notch Apoptosis	Neurological Disease Inflammation/Immunology Cancer
DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC₅₀s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ₄₂, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment .

HY-B0116S

Stavudine-d4	Isotope-Labeled Compounds Reverse Transcriptase HIV Nucleoside Antimetabolite/Analog NOD-like Receptor (NLR) Autophagy Apoptosis	Infection
Stavudine-d₄ is the deuterium labeled Stavudine. Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis[1][2][3][4].

HY-B0116R

Stavudine (Standard)	Reverse Transcriptase HIV Nucleoside Antimetabolite/Analog NOD-like Receptor (NLR) Autophagy Apoptosis	Infection
Stavudine (Standard) is the analytical standard of Stavudine. This product is intended for research and analytical applications. Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis .

HY-19918A

Anatabine dicitrate	NF-κB Amyloid-β nAChR	Neurological Disease Inflammation/Immunology
Anatabine dicitrate is a tobacco alkaloid that can cross the blood-brain barrier. Anatabine dicitrate is a potent α4β2 nAChR agonist. Anatabine dicitrate inhibits NF-κB activation lower amyloid-β (Aβ) production by preventing the β-cleavage of amyloid precursor protein (APP). Anatabine dicitrate has anti-inflammatory effects and has the potential for neurodegenerative disorders treatment .

HY-157440

AChE/Aβ-IN-3	Amyloid-β Reactive Oxygen Species Cholinesterase (ChE)	Neurological Disease
AChE/Aβ-IN-3 (compound AM5) is a dual inhibitor of AChE and *Amyloid-β* aggregation with IC_50<.sub> values of 1.29 and 4.93 μM, respectively. AChE/Aβ-IN-3 has antioxidant properties that scavenge ROS and restore their normal levels. AChE/Aβ-IN-3 can be used in the study of neurological diseases, such as Alzheimer's disease .

HY-16009B

Buntanetap L-Tartrate (+)-Phenserine L-Tartrate; ANVS401 L-Tartrate	Amyloid-β	Cancer
Buntanetap (L-Tartrate) is an orally administered small molecule inhibitor of several neurotoxic proteins. Buntanetap reduces amyloid precursor protein (APP) production by blocking its mRNA translation .

HY-149211

AChE/BChE-IN-12	Cholinesterase (ChE) Beta-secretase Amyloid-β	Neurological Disease
AChE/BChE-IN-12 (compound 10b), a 3,5-dimethoxy analogue, is a potent AChE, BChE, and β-secretase-1 (BACE-1) inhibitor, with IC₅₀ values of 2.57, 3.26, and 10.65 μM, respectively. AChE/BChE-IN-12 crosses the blood-brain barrier via passive diffusion and inhibits the self-aggregation of *amyloid-β* monomers. AChE/BChE-IN-12 can be used for Alzheimer’s disease (AD) research .

HY-147820

AY1511	Amyloid-β	Neurological Disease
AY1511 is an amyloid β (Aβ) aggregation inhibitor with low cytotoxicity .

HY-123357

IMM-H004	Apoptosis	Neurological Disease
IMM-H004, a coumarin derivative, possesses neuroprotective and potent free radical scavenging abilities. IMM-H004 significantly inhibits amyloid-β (Aβ)-induced cytotoxicity and apoptosis, offering potential value for research into neurodegenerative diseases such as Alzheimer's disease. Additionally, IMM-H004 is also capable of effectively blocking the calcium mobilization and chemotaxis induced by CKLF1-C27 (HY-P3418), thereby alleviating asthmatic pathological changes in the lung tissue of CKLF1 transgenic mice .

HY-162832

Amyloid-β-IN-1	Amyloid-β	Neurological Disease
Amyloid-β-IN-1 (compound 13) is a synthetic peptide containing the hydrophobic C-terminal region "VVIA-NH2" and its reverse sequence "AIVV-NH2" of Aβ₄₂, which is an Aβ inhibitor. Amyloid-β-IN-1 can inhibit Aβ aggregation and has neuroprotective effects .

HY-146483

Anti-Aβ agent 1A	Amyloid-β	Neurological Disease Inflammation/Immunology
Anti-Aβ agent 1A (compound M15) has potent activity against *amyloid-β. Anti-Aβ agent 1A possesses can significantly inhibit* LPS-induced levels of IL-1β, IL-6 and TNF-α, and reduces the apoptosis of SH-SY5Y induced by H₂O₂ through mitochondria pathway. Anti-Aβ agent 1A possesses antioxidant, anti-inflammatory, anti-Aβ toxicity and neuroprotective activities. Anti-Aβ agent 1A can be used for researching Alzheimer’s disease (AD) .

HY-124322

NB-360	Beta-secretase	Neurological Disease Inflammation/Immunology
NB-360 is a potent, brain penetrable, and orally bioavailable dual BACE1/BACE2 inhibitor (IC₅₀: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloid precursor protein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E .

HY-123485

PPI-1019	Amyloid-β	Neurological Disease
PPI-1019 is an amyloid beta (Aβ) inhibitor. PPI-1019 can be used in the research of neurological diseases and Alzheimer's disease .

HY-P10611

[D-Ser14]-Humanin	Amyloid-β	Neurological Disease
[D-Ser14]-Humanin is a bioactive peptide in which the Ser14 residue of Humanin (HY-P1928) is changed from L-form to D-form. [D-Ser14]-Humanin has potent inhibitory activity against the fibrillation of *amyloid-β. Humanin (HY-P1928) inhibits* the aging-related death of various cells caused by amyloid fibrils and oxidative stress, and [D-Ser14]-Humanin has better cell protection activity than Humanin (HY-P1928). [D-Ser14]-Humanin can be used in the study of Alzheimer's disease .

HY-157296

AChE-IN-47	Cholinesterase (ChE)	Neurological Disease
AChE-IN-47 (compound g17) is a AChE inhibitor with the IC₅₀ of 0.24 μM. AChE-IN-47 inhibits amyloid β peptides self-aggregation. AChE-IN-47 displays neuroprotective effects and effectively suppresses the intracellular accumulation of reactive oxygen species .

HY-159083

DN5355	Amyloid-β	Neurological Disease
DN5355 is a small molecule compound that targets amyloid β protein (Aβ) and hyperphosphorylated tau protein. DN5355 can inhibit the aggregation of Aβ and tau protein and disaggregate the formed Aβ and tau protein fibers. DN5355 can be used in the study of Alzheimer's disease .

HY-161658

Aβ-IN-9	Amyloid-β	Neurological Disease
Aβ-IN-9 (Compound 6i) is an *amyloid-beta* aggregation inhibitor. Aβ-IN-9 can inhibit Aβ aggregation to form nano-rod-like structures, thereby preventing β-sheet formation. Aβ-IN-9 can be used for Alzheimer's disease research .

HY-N1280

Semilicoisoflavone B	Amyloid-β	Neurological Disease
Semilicoisoflavone B, an isoflavone, mainly derived from Glycyrrhiza uralensis Fisch.. Semilicoisoflavone B reduces *amyloid β* (Aβ) secretion by inhibiting β-secretase-1 (BACE1) expression and activity. Semilicoisoflavone B decreases BACE1 expression mainly through increasing PPARγ expression and inhibiting STAT3 phosphorylation .

HY-N0249

Saikosaponin C	Amyloid-β	Neurological Disease
Saikosaponin C is a bioactive component found in radix bupleuri, targets *amyloid beta* and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression .

HY-146347

MAO-B-IN-10	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated MAO-B (monoamine oxidase-B) inhibitor, with IC₅₀ of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research .

HY-103383

(R)-DRF053 dihydrochloride	CDK Casein Kinase	Neurological Disease Cancer
(R)-DRF053 dihydrochloride is a potent casein kinases 1 (CK1), CDK1/cyclin B and CDK5/p25 inhibitor with IC₅₀s of 14 nM, 220 nM and 80 nM, respectively. (R)-DRF053 dihydrochloride prevents the CK1-dependent production of amyloid-beta in a cell model .

HY-169022

4-FPBUA	Autophagy mTOR	Neurological Disease
4-FPBUA is a semisynthetic analog of usnic acid (HY-W015883) that can enhance cellular blood-brain barrier (BBB) function and increase the transport of Amyloid β (Aβ) across monolayer cells. 4-FPBUA is also an inhibitor of mTOR, capable of enhancing cellular Autophagy, thereby reversing BBB disruption in vivo and being utilized in research for Alzheimer's disease .

HY-146140

Aβ-IN-4	Amyloid-β	Neurological Disease
Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-146139

Aβ-IN-3	Amyloid-β	Neurological Disease
Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one .

HY-100740A

Lanabecestat hydrochloride AZD-3293 hydrochloride; LY3314814 hydrochloride	Others	Neurological Disease
Lanabecestat (AZD-3293) hydrochloride is a potent BACE1 inhibitor that has been investigated for its potential as a modifying treatment for Alzheimer's disease. Lanabecestat (hydrochloride) demonstrated significant dose- and time-dependent reductions in concentrations of amyloid beta peptides in plasma, cerebrospinal fluid, and brain. Lanabecestat (hydrochloride) was also shown to produce reductions in Aβ neuritic plaque burden without demonstrating clinical benefits or slowing the progression of Alzheimer's disease pathophysiology.

HY-N0249R

Saikosaponin C (Standard)	Amyloid-β	Neurological Disease
Saikosaponin C (Standard) is the analytical standard of Saikosaponin C. This product is intended for research and analytical applications. Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression .

HY-120597

SAK3	Calcium Channel	Neurological Disease
SAK3 is a potent T-type voltage-gated Ca ²⁺ channels (T-VGCCs) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca ²⁺ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice . SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity .

HY-136813

Multitarget AD inhibitor-1	Beta-secretase Amyloid-β Cholinesterase (ChE)	Neurological Disease
Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC₅₀s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC_50hBACE-1=41.60 μM), *amyloid β* aggregation (IC_50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research .

HY-N0373

Licochalcone B 5 Publications Verification	Amyloid-β Apoptosis NOD-like Receptor (NLR)	Neurological Disease
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits *amyloid β* (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-N6640

2-O-Acetyl-20-hydroxyecdysone 20-Hydroxyeedysone 2-acetate	Amyloid-β	Neurological Disease
2-O-Acetyl-20-hydroxyecdysone, an ecdysterones in insects and terrestrial plants, inhibits amyloid-β₄₂ (Aβ₄₂)-induced cytotoxicity. 2-O-Acetyl-20-hydroxyecdysone could decrease Aβ oligomer formation through promotion of fibrogenesis, transforming Aβ oligomers to the low-toxicity fibrils .

Cat. No.	Product Name	Target	Research Area